TP53 mutations upregulate RCP expression via Sp1/3 to drive lung cancer progression

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Mutant p53 (mtp53) exhibits gain-of-function activities promoting cancer.
• The regulatory mechanisms of mtp53, particularly concerning its impact on gene transcription, are not fully understood.
• Understanding these mechanisms is crucial for developing targeted therapies for p53-mutant cancers.

Purpose of the Study:

• To elucidate the mechanism by which mtp53 regulates Rab coupling protein (RCP) transcription.
• To investigate the role of RCP in lung cancer progression and metastasis.
• To identify the transcriptional regulators involved in RCP expression and their interaction with p53.

Main Methods:

• Quantitative analysis of RCP expression in lung cancer tissues and cells.
• Functional studies using RCP knockout models to assess tumor growth and metastasis.
• Mass spectrometry and co-immunoprecipitation to identify RCP transcriptional activators.
• Western blotting and chromatin immunoprecipitation assays to study p53-Sp1/3 interactions and their effect on RCP transcription.

Main Results:

• RCP is highly expressed in lung cancer and its knockout suppresses tumor growth and metastasis.
• Sp1, Sp3, and Stat3 were identified as key transcriptional activators of RCP.
• Wild-type p53 suppresses RCP transcription by reducing Sp1/3 levels, while mtp53, through loss-of-function, alters Sp1/3 expression.
• Gain-of-function mtp53 mutants enhance binding to Sp1/3, leading to increased RCP transcription and promoting lung cancer progression.

Conclusions:

• This study reveals a novel mechanism where mtp53 promotes lung cancer by upregulating RCP transcription via altered interactions with Sp1/3.
• The findings highlight the critical role of RCP in lung cancer progression and metastasis.
• This work provides new therapeutic insights for targeting p53-mutant lung cancers by modulating the mtp53-RCP pathway.